 3. above 60 years with high risk features cytogenetics, secondary or treatment related AML d above 60 years with myelodysplastic syndrome with 10 blasts in bone marrow WHO RAEB-2 Refractory anemia with excess blasts-2. For patients below 60 years potential curative treatments should have been exhausted. 